Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

CureVac Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

CureVac şirketinin toplam hissedar öz sermayesi €376.5M ve toplam borcu €0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla €556.8M ve €180.3M dir.

Anahtar bilgiler

Borç/özkaynak oranı

€0

Borç

Faiz karşılama oranı	n/a
Nakit	€202.52m
Eşitlik	€376.53m
Toplam yükümlülükler	€180.30m
Toplam varlıklar	€556.84m

Son finansal sağlık güncellemeleri

Recent updates

CureVac N.V.'s (NASDAQ:CVAC) Share Price Could Signal Some Risk

Sep 16

CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 93% Above Its Share Price

Aug 03

We're Hopeful That CureVac (NASDAQ:CVAC) Will Use Its Cash Wisely

Jul 05

CureVac: GSK's Deal For Infectious Disease Assets Is A Long-Shot For Both Pharmas

Jul 04

Optimistic Investors Push CureVac N.V. (NASDAQ:CVAC) Shares Up 47% But Growth Is Lacking

Jun 01

We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully

Mar 20

CureVac: No Momentum In Sight

Mar 08

What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates

Aug 26

CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price

Jun 14

Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates

May 01

Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results

Apr 29

An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued

Jan 08

CureVac BV reports Q2 results

Aug 18

CureVac claims patent rights for Pfizer/BioNTech COVID-19 vaccine

Jul 05

Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?

May 29

Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week

May 02

A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)

Oct 28

CureVac: Wait For Concrete News Before Investing

Sep 01

CureVac plunges as COVID-19 vaccine candidate indicates below par efficacy

Jun 16

An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued

Jun 13

CureVac tumbles on potential delay for European decision on its COVID-19 shot

Jun 08

CureVac: The Moment Of Truth Arrives

Jun 01

CureVac BV reports Q1 results

May 26

CureVac Could Soon Join The Fight Against COVID-19

May 10

CureVac N.V.'s (NASDAQ:CVAC) Has Found A Path To Profitability

May 02

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: CVAC 'nin kısa vadeli varlıkları ( €251.6M ) kısa vadeli yükümlülüklerini ( €110.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: CVAC şirketinin kısa vadeli varlıkları ( €251.6M ) uzun vadeli yükümlülüklerini ( €70.3M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: CVAC borçsuzdur.

Borcun Azaltılması: CVAC şu anda borcu yok ancak 5 yıl öncesine ait verimiz olmadığı için karşılaştırma yapamıyoruz.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: CVAC şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: CVAC tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

CureVac Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We're Hopeful That CureVac (NASDAQ:CVAC) Will Use Its Cash Wisely

We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully

Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?

Recent updates

CureVac N.V.'s (NASDAQ:CVAC) Share Price Could Signal Some Risk

CureVac N.V. to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

CureVac N.V. Announces Pierre Kemula, Chief Financial Officer, to Step Down At the End of His Term October 31, 2024

CureVac N.V. to Report Q2, 2024 Results on Aug 15, 2024

CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 93% Above Its Share Price

We're Hopeful That CureVac (NASDAQ:CVAC) Will Use Its Cash Wisely

CureVac: GSK's Deal For Infectious Disease Assets Is A Long-Shot For Both Pharmas

CureVac N.V. Approves the Appointment of Birgit Hofmann as a Member of the Supervisory Board

Optimistic Investors Push CureVac N.V. (NASDAQ:CVAC) Shares Up 47% But Growth Is Lacking

CureVac N.V. Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK

New major risk - Financial position

CureVac N.V. to Report Q1, 2024 Results on May 23, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer, Effective June 1, 2024

CureVac N.V. to Report Q4, 2023 Results on Apr 24, 2024

CureVac N.V. Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK

We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully

CureVac: No Momentum In Sight

CureVac N.V. Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

CureVac N.V. Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK

CureVac N.V. to Report Q3, 2023 Results on Nov 14, 2023

Consensus EPS estimates fall by 17%

Consensus revenue estimates increase by 13%, EPS downgraded

What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 29%, EPS upgraded

CureVac N.V. to Report Q2, 2023 Results on Aug 17, 2023

CureVac N.V. Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 Mrna Vaccine Candidates Developed in Collaboration with GSK

CureVac N.V. Announces Executive Changes

CureVac N.V. Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma

Consensus revenue estimates increase by 57%

CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price

Consensus revenue estimates decrease by 42%, EPS upgraded

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

CureVac N.V., Annual General Meeting, Jun 19, 2023

CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK

Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates

Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results

Full year 2022 earnings: EPS and revenues miss analyst expectations

CureVac N.V. Appoints Myriam Mendila as New Chief Development Officer

CureVac N.V. Announces Positive Data in Older Adults from Covid-19 and Flu mRNA Vaccine Development Programs

Now 31% undervalued

CureVac N.V. Announces CEO Changes

An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued

Third quarter 2022 earnings released: €0.25 loss per share (vs €0.77 loss in 3Q 2021)

CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102

CureVac N.V. to Report Q3, 2022 Results on Nov 16, 2022

No longer forecast to breakeven

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

CureVac Announces Executive Changes

CureVac BV reports Q2 results

Consensus estimates of losses per share improve by 10%

CureVac claims patent rights for Pfizer/BioNTech COVID-19 vaccine

CureVac N.V. Announces Board Changes

CureVac N.V. (NasdaqGM:CVAC) acquired Frame Therapeutics B.V. for €32 million.

CureVac N.V. Announces Changes of CDO

CureVac N.V., Annual General Meeting, Jun 22, 2022

Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?

Insider notifies of intention to sell stock

Consensus forecasts updated

Consensus forecasts updated

Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 36%

Forecast breakeven date pushed back to 2024

CureVac N.V. to Report Q4, 2021 Results on Apr 28, 2022

CureVac N.V Announces Preclinical Data Demonstrating Immune Responses and Protective Efficacy of Bivalent Second-Generation COVID-19 Vaccine Candidate Jointly Developed with GSK

CureVac N.V. and GSK Start Clinical Development of Second-Generation Covid-19 Vaccine Candidate, CV2CoV

CureVac N.V. Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK

Forecast breakeven date pushed back to 2024

Forecast breakeven date pushed back to 2023